問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Cardiovascular Diseases

Division of General Internal Medicine

Division of Neurology

Division of Thoracic Medicine

更新時間：2023-09-19

白培英Pai, Pei-Ying
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

白培英

List

27Cases

2013-01-10 - 2015-12-31

Phase III

A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C

  • Condition/Disease

    Hyperlipidemia

  • Test Drug

    MK859/Placebo

Participate Sites
9Sites

Terminated9Sites

2010-08-30 - 2012-11-30

Phase III

A Phase III, Prospective, Randomized, Double-Blind, PlaceboControlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients with Atrial Fibrillation

  • Condition/Disease

    Atrial Fibrillation

  • Test Drug

    MK-6621

Participate Sites
16Sites

Terminated16Sites

2009-10-31 - 2013-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2008-01-02 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-02-01 - 2010-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2009-02-15 - 2012-09-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Terminated16Sites

2010-06-30 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2017-07-28 - 2018-12-31

Phase II

A multi-center, randomized, double-blind, parallel-group　dose-finding study to assess the effect of 3 doses of　LIK066 compared to placebo or empagliflozin in type 2　diabetes mellitus patients with heart failure

  • Condition/Disease

    type 2　diabetes mellitus patients with heart failure

  • Test Drug

    LIK066

Participate Sites
4Sites

Terminated3Sites

2014-11-01 - 2019-05-31

Phase III

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Condition/Disease

    Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Test Drug

    LCZ696

Participate Sites
9Sites

Terminated9Sites

2014-12-01 - 2017-09-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB